A carregar...
Vandetanib and cabozantinib potentiate mitochondria-targeted agents to suppress medullary thyroid carcinoma cells
Although the FDA-approved receptor tyrosine kinases inhibitors, vandetanib and cabozantinib, are used to treat surgically inoperable progressive medullary thyroid carcinoma (MTC), not all patients are responsive while the disease sometimes progresses after an initial response. To better understand M...
Na minha lista:
| Publicado no: | Cancer Biol Ther |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Taylor & Francis
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5639831/ https://ncbi.nlm.nih.gov/pubmed/28475408 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384047.2017.1323594 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|